Quidel

News Releases

Webcast ImageWebcast
Q3 2017 Quidel Corporation Earnings Conference Call (Live)
11/01/17 at 2:00 p.m. PT
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Date Title
10/17/17Quidel Receives FDA Clearance for Its Solana® RSV + hMPV Assay
10/13/17Quidel to Hold Third Quarter 2017 Financial Results Conference Call on November 1, 2017
10/06/17Quidel Announces Closing of Acquisition of Alere Triage® Assets Creating an Expanded Portfolio of Rapid Diagnostic Capabilities in Critical Care Settings
09/28/17Quidel Announces Early Termination of the Hart-Scott-Rodino Waiting Period for Its Pending Acquisition of Alere’s Triage® B-type Naturietic Peptide (BNP) Assay Business Run on Beckman Coulter Analyzers
09/18/17Quidel Announces Revised Agreement for Its Pending Acquisition of Alere’s B-type Naturietic Peptide (BNP) Assay Business Run on Beckman Coulter Analyzers
09/08/17Quidel to Participate in the CEO Series Conference Call Hosted by Canaccord Genuity
07/31/17Quidel to Present at the 37th Annual Canaccord Genuity Growth Conference
07/26/17Quidel Reports Second Quarter 2017 Financial Results
07/17/17Quidel Announces Definitive Agreement to Acquire Alere Triage® Assets
07/14/17Quidel to Hold Second Quarter 2017 Financial Results Conference Call on July 26, 2017
06/28/17Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Instrument for Use with Sofia Respiratory Syncytial Virus (RSV) Assay
06/22/17Quidel’s Sofia® 2 Point-of-Care Immunoassay Analyzer Receives Multiple Awards from Good Design Australia®’s 2017 Good Design Awards®
06/07/17Quidel Receives the CE Mark for Its Thyretain® TBI Reporter BioAssay
05/30/17Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Immunoassay Analyzer for Use with Sofia Influenza A+B Assay
05/24/17Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay
05/16/17Quidel Completes Acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses
05/11/17Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Clostridium difficile (C. difficile) Infections
05/01/17Quidel to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
04/24/17Quidel Reports First Quarter 2017 Financial Results
04/11/17Quidel to Hold First Quarter 2017 Financial Results Conference Call on April 24, 2017
03/02/17Quidel to Present at the Barclays Global Healthcare Conference
02/08/17Quidel Reports Fourth Quarter and Full Year 2016 Financial Results
01/25/17Quidel to Hold Fourth Quarter and Full Year 2016 Financial Results Conference Call on February 8, 2017
01/23/17Quidel Announces Modification of Revenue Reporting Categories
01/06/17Quidel Announces Preliminary Revenue for Fourth Quarter 2016
12/20/16Quidel to Present at 35th Annual J.P. Morgan Healthcare Conference
11/29/16Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Herpes Simplex Virus 1+2 and Varicella Zoster Virus
11/17/16Quidel to Present at the 28th Annual Piper Jaffray Healthcare Conference
10/26/16Quidel Reports Third Quarter 2016 Financial Results
10/25/16Quidel Receives FDA Clearance for Its New Solana(R) Strep Complete Assay for Rapid and Qualitative Detection and Differentiation of S. pyogenes (Group A Beta-Hemolytic Streptococcus) and S. dysgalactiae (Pyogenic Group C and G Beta-Hemolytic Streptococcus)
10/12/16Quidel to Hold Third Quarter 2016 Financial Results Conference Call on October 26, 2016
09/27/16Quidel Receives FDA Clearance for Its Solana(R) Influenza A+B Assay in Time for the Upcoming 2016-2017 Flu Season
08/24/16Quidel to Present at 2016 Wells Fargo Healthcare Conference
08/17/16Quidel Receives FDA Clearance for Its Solana(R) Trichomonas Assay for Diagnosis of Trichomoniasis
07/28/16Quidel to Present at the 36th Annual Canaccord Genuity Growth Conference
07/27/16Quidel Reports Second Quarter 2016 Financial Results
07/13/16Quidel to Hold Second Quarter 2016 Financial Results Conference Call on July 27, 2016
07/12/16Genome Web: Quidel’s Solana Group A Strep Test Fares Well in Prospective Evaluation
04/28/16Quidel to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
04/27/16Quidel Reports First Quarter 2016 Financial Results
04/12/16Quidel to Hold First Quarter 2016 Financial Results Conference Call on April 27, 2016
02/17/16Quidel Reports Fourth Quarter and Full Year 2015 Financial Results
02/03/16Quidel to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call on February 17, 2016
01/25/16Quidel Receives CE Mark for Its New Sofia(R) Fluorescent Immunoassay for Diagnosis of Pneumococcal Pneumonia and Pneumococcal Meningitis
01/07/16Quidel Announces Preliminary Revenue for Fourth Quarter 2015
11/17/15Charlie Slacik Joins Quidel's Board of Directors
10/28/15Quidel Reports Third Quarter 2015 Financial Results
10/07/15Quidel to Hold Third Quarter 2015 Financial Results Conference Call on October 28, 2015
08/27/15Quidel to Present at 10th Annual Wells Fargo Healthcare Conference
08/19/15Quidel Announces Changes to Board of Directors
07/22/15Quidel Reports Second Quarter 2015 Financial Results
07/07/15Quidel to Hold Second Quarter 2015 Financial Results Conference Call on July 22, 2015
06/23/15Quidel Receives FDA Clearance for Its New Solana(TM) Molecular System and Solana(TM) Molecular Assay for Diagnosis of Group A Streptococcal Infections
05/28/15Quidel to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
04/29/15Quidel to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
04/23/15Quidel Reports First Quarter 2015 Financial Results
04/09/15Quidel to Hold First Quarter 2015 Financial Results Conference Call on April 23, 2015
03/17/15Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic Test for Trichomoniasis
02/24/15Quidel to Present at Upcoming Conferences
02/11/15Quidel Reports Fourth Quarter and Full Year 2014 Financial Results
01/28/15Quidel to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call on February 11, 2015
01/05/15Quidel to Present at 33rd Annual J.P. Morgan Healthcare Conference
12/17/14Quidel Receives Simultaneous FDA Clearance and CLIA Waiver for Its Sofia(R) Strep A+ Fluorescent Immunoassay (FIA) via the FDA's New Dual Submission Program
12/10/14Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Bordetella Pertussis
12/02/14Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering
12/01/14Quidel Announces Proposed Offering of $150 Million of Convertible Senior Notes
11/18/14Dr. Kenneth J. Widder Joins Quidel's Board of Directors
10/21/14Quidel Reports Third Quarter 2014 Financial Results
10/15/14Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parainfluenza Viruses (HPIV), Types 1, 2 and 3
10/13/14Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus
10/06/14Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014
08/22/14Quidel to Present at Baird 2014 Health Care Conference
07/28/14Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test for Group A Strep
07/22/14Quidel Reports Second Quarter 2014 Financial Results
07/08/14Quidel to Hold Second Quarter 2014 Financial Results Conference Call on July 22, 2014
06/04/14Quidel to Present at Wells Fargo Securities 2014 Healthcare Conference
06/02/14Quidel Receives CLIA Waiver for Its Sofia(R) Diagnostic Test for Respiratory Syncytial Virus (RSV)
05/14/14Quidel Receives FDA Clearance for Its Molecular PCR Assay for the Detection of Herpes Simplex Virus 1+2 and Varicella Zoster Virus
04/29/14Quidel to Present at Bank of America Merrill Lynch 2014 Health Care Conference
04/23/14Quidel Reports First Quarter 2014 Financial Results
04/22/14Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Infections From Pyogenic Streptococcus Group A and C or G
04/15/14Quidel to Hold First Quarter 2014 Financial Results Conference Call on April 23, 2014
03/27/14Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Herpes Simplex Virus Types 1 and 2
02/18/14Quidel to Present at Cowen 34th Annual Health Care Conference
02/11/14Quidel Reports Fourth Quarter and Full Year 2013 Financial Results
01/28/14Quidel to Hold Fourth Quarter and Full Year 2013 Financial Results Conference Call on February 11, 2014
01/08/14Quidel Announces Preliminary Revenue for Fourth Quarter 2013
12/30/13Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
10/31/13Quidel to Present at Upcoming Conferences
10/23/13Quidel Reports Third Quarter 2013 Financial Results
10/07/13Quidel to Hold Third Quarter 2013 Financial Results Conference Call on October 23, 2013
09/16/13Quidel Receives Two FDA Clearances for Molecular Diagnostic Tests for Use on Life Technologies QuantStudio(TM) Dx
08/19/13Quidel Receives FDA Clearance for Its Sofia(R) RSV Fluorescent Immunoassay (FIA)
08/05/13Quidel Receives FDA Clearance for Its Sofia(R) hCG Fluorescent Immunoassay (FIA)
07/30/13Quidel Reports Second Quarter 2013 Financial Results
07/15/13Quidel to Hold Second Quarter 2013 Financial Results Conference Call on July 30, 2013
07/15/13Quidel Obtains Special 510(k) Clearance to Add Avian Influenza A (H7N9) Virus Analytical Reactivity Information to the Package Inserts for All Three of Its Rapid Diagnostic Tests for Influenza
06/20/13Quidel Receives FDA Clearance for Its Sofia(R) Strep A Fluorescent Immunoassay (FIA)
06/04/13Quidel to Present at William Blair & Company 33rd Annual Growth Stock Conference
05/08/13Quidel to Present at Bank of America Merrill Lynch 2013 Health Care Conference
05/06/13Quidel Completes Acquisition of BioHelix Corporation
04/23/13Quidel Reports First Quarter 2013 Financial Results
04/10/13Quidel to Hold First Quarter 2013 Financial Results Conference Call on April 23, 2013
03/25/13Quidel Receives CE Mark for Its Molecular Diagnostic Test for Herpes Simplex Viruses (HSV 1, HSV 2) and Varicella-Zoster Virus (VZV)
03/18/13Quidel and Life Technologies Receive FDA Clearance for Clostridium difficile Assay and QuantStudio™ Dx and 7500 Fast Dx Real-Time PCR Instruments
03/12/13Quidel Receives FDA Clearance for Its Molecular Diagnostic Test for Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV)
02/25/13Quidel to Host 2013 Analyst and Investor Day in Boston
02/25/13Quidel to Present at Cowen 33rd Annual Health Care Conference
02/12/13Quidel Reports Fourth Quarter and Full Year 2012 Financial Results
01/31/13Quidel to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on February 12, 2013
01/04/13Quidel Announces Preliminary Revenue for Fourth Quarter 2012
01/02/13Quidel to Present at 31st Annual J.P. Morgan Healthcare Conference
12/17/12Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Clostridium Difficile
11/20/12Quidel to Present at 24th Annual Piper Jaffray Healthcare Conference
11/07/12Quidel Receives CE Mark for Its Sofia(R) Legionella Fluorescent Immunoassay (FIA)
11/07/12Quidel to Present at Credit Suisse 2012 Healthcare Conference
10/23/12Quidel Reports Third Quarter 2012 Financial Results
10/09/12Quidel to Hold Third Quarter 2012 Financial Results Conference Call on October 23, 2012
09/18/12Quidel Receives CE Mark for Its Sofia(R) RSV Fluorescent Immunoassay (FIA) Test
08/10/12Quidel Secures New $140 Million Credit Facility
07/31/12Quidel to Present at Canaccord Genuity 32nd Annual Growth Conference
07/25/12Quidel Reports Second Quarter 2012 Financial Results
07/10/12Quidel to Hold Second Quarter 2012 Financial Results Conference Call on July 25, 2012
05/31/12Quidel to Present at Upcoming Conferences
04/25/12Quidel Reports First Quarter 2012 Financial Results
04/20/12Quidel Receives CLIA Waiver for Its Sofia(TM) Analyzer and Sofia Influenza A+B Fluorescent Immunoassay (FIA)
04/13/12Quidel to Hold First Quarter 2012 Financial Results Conference Call on April 25, 2012
04/02/12Quidel Receives CE Mark for Its Direct Specimen Rapid PCR Test for Toxigenic Clostridium Difficile
03/27/12Quidel Receives CE Mark for Its AmpliVue(TM) Hand-Held Molecular Diagnostic Test for Clostridium Difficile
03/22/12Quidel Receives FDA Clearance for Its Quidel Molecular(TM) Influenza A+B Assay for Use With Cepheid SmartCycler(R)
03/12/12Quidel Receives CE Mark for Its Molecular Diagnostic Test for Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV)
02/29/12Quidel Reports Fourth Quarter and Full Year 2011 Financial Results
02/02/12Quidel to Hold Fourth Quarter and Full Year 2011 Financial Results Conference Call on February 29, 2012
01/04/12Quidel to Present at 30th Annual J.P. Morgan Health Care Conference
12/23/11Quidel Receives FDA Clearance for Its Quidel Molecular Influenza A+B Assay
12/23/11Quidel Receives FDA Clearance for Its Quidel Molecular Human Metapneumovirus (hMPV) Assay
12/01/11Quidel Receives CE Mark for Its Sofia(TM) Strep A Fluorescent Immunoassay (FIA) Test
11/18/11Quidel to Present at 23rd Annual Piper Jaffray Health Care Conference
11/02/11Quidel to Present at Credit Suisse 2011 Health Care Conference
10/26/11Quidel Receives 510(k) Clearance of Its Sofia(TM) Fluorescent Immunoassay Analyzer and Influenza A+B FIA Test
10/25/11Quidel Reports Third Quarter 2011 Financial Results
10/04/11Quidel to Hold Third Quarter 2011 Financial Results Conference Call on October 25, 2011
09/21/11Quidel Receives CE Mark for Its Molecular Diagnostic Test for Human Metapneumovirus (hMPV)
08/16/11Quidel Receives CE Mark for Its Sofia Fluorescent Immunoassay Analyzer and Influenza A+B FIA Test
08/05/11Quidel Receives CE Mark for Its First Molecular Diagnostic Test
08/02/11Quidel Reports Second Quarter 2011 Financial Results
07/19/11Quidel to Hold Second Quarter 2011 Financial Results Conference Call on August 2, 2011
05/05/11Quidel to Present at Bank of America Merrill Lynch Health Care Conference
04/28/11Quidel Reports First Quarter 2011 Financial Results
04/15/11Quidel to Hold First Quarter 2011 Financial Results Conference Call on April 28, 2011
04/01/11Quidel to Host 2011 Analyst Day in Boston
02/25/11Quidel to Present at Citi 2011 Global Health Care Conference
02/24/11Quidel Reports Fourth Quarter and Full Year 2010 Results
02/04/11Quidel to Hold Fourth Quarter and Full Year 2010 Results Conference Call on February 24, 2011
01/07/11Quidel to Present at JP Morgan 29th Annual Healthcare Conference
01/06/11Quidel Announces Pricing of Common Shares Offering
01/05/11Quidel Announces Proposed Common Shares Offering
10/27/10Quidel Reports Third Quarter 2010 Results
10/13/10Quidel to Hold Third Quarter 2010 Results Conference Call on October 27, 2010
09/29/10Quidel Announces FDA Clearance of Its QuickVue(R) RSV 10 Immunoassay Diagnostic Test
08/31/10Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test
08/04/10Quidel to Present at Canaccord Genuity 30th Annual Growth Conference
07/30/10Quidel to Present at Wedbush Life Sciences Best Ideas Management Access Conference
07/29/10Quidel Reports Second Quarter 2010 Results
07/26/10Quidel Announces the Availability of Its QuickVue(R)+Infectious Mononucleosis Lateral Flow Diagnostic Test
07/09/10Quidel to Hold Second Quarter 2010 Results Conference Call on July 29, 2010
07/01/10Diagnostic Hybrids Receives Approval from Chinese SFDA for D3(R)Ultra(TM) DFA Respiratory Virus Screening and ID Kit
04/29/10Quidel Reports First Quarter 2010 Results
04/15/10Quidel to Hold First Quarter 2010 Results Conference Call on April 29, 2010
02/23/10Diagnostic Hybrids Receives FDA Emergency Use Authorization for D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
02/19/10Quidel Corporation Completes Acquisition of Diagnostic Hybrids
02/11/10Quidel Reports Fourth Quarter and Full Year 2009 Results
01/29/10Quidel to Hold Fourth Quarter and Full Year 2009 Results Conference Call on February 11, 2010
01/10/10Quidel Corporation Announces Definitive Agreement to Acquire Diagnostic Hybrids
01/04/10Quidel Corporation to Present at the 28th Annual J.P. Morgan Healthcare Conference
12/08/09Quidel Authorizes Additional $25 Million under Stock Repurchase Program
10/16/09Quidel Reports Third Quarter 2009 Results
10/16/09Quidel Announces Launch of Their MicroVue(R) C5a EIA Kit for Research Use Only
10/06/09Quidel Corporation Announces Joint Development and Commercialization Agreement with BioHelix Corporation
09/22/09Quidel to Present at the William Blair & Company Emerging Growth Stock Conference
09/18/09Quidel Issues Clarification Regarding Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Reactivity Information to the QuickVue Influenza A+B Test Package Insert
09/17/09Quidel Obtains Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Reactivity Information to the QuickVue Influenza A+B Test Package Insert
09/10/09Quidel Anticipates Record Quarterly Results Driven by Strong Demand for Flu Tests
09/10/09Quidel to Present at Investor Conferences in September
08/10/09Quidel Launches Flu Test Educational Programs for the Clinical Community
08/06/09Quidel Announces Executive Appointments
07/22/09Quidel Reports Second Quarter 2009 Results
07/09/09Quidel to Hold 2009 Second Quarter Conference Call on July 22, 2009
06/10/09Quidel Corporation to Attend the Sixth Annual Craig-Hallum Institutional Investor Conference
04/22/09Quidel Reports First Quarter 2009 Results
04/08/09Quidel to Hold 2009 First Quarter Conference Call on April 22, 2009
03/31/09Quidel Announces Strategic Restructuring and Work Force Reduction
03/16/09Quidel Provides Update on Impact of Current Influenza Season and Macroeconomic Trends
03/13/09Quidel Schedules Conference Call for March 16, 2009 to Provide Business Update
02/25/09Quidel Reports Fourth Quarter and Full Year 2008 Results
02/18/09Quidel Corporation Webinar Addresses Management of Influenza in Long-Term Care Facilities
02/10/09Quidel to Hold 2008 Fourth Quarter and Year-End Financial Results Conference Call on February 25, 2009
01/20/09Quidel Corporation Appoints Douglas C. Bryant President & Chief Executive Officer
01/19/09Quidel Launches rsvtesting.com; Web Site Delivers Practical Information on Respiratory Syncytial Virus (RSV)
01/06/09Quidel Corporation to Present at the 27th Annual J.P. Morgan Healthcare Conference
01/05/09Caren L. Mason, President & CEO, to Retire from Quidel in 2009
12/09/08Quidel's QuickVue(R) iFOB Test Results Show High Correlation with Quantitative Laboratory Assay for Fecal Occult Blood Using Stools from Patients with Post-Colonoscopy Based Clinical Diagnosis
12/02/08Quidel Authorizes Additional $25 Million under Stock Repurchase Program
12/01/08Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference
11/07/08Quidel Announces Promotion of John Tamerius, Ph.D. to Senior Vice President, Clinical/Regulatory Affairs
10/22/08Quidel Reports Third Quarter 2008 Results
10/09/08Quidel Corporation Secures New $120 Million Credit Facility
10/08/08Quidel to Hold 2008 Third Quarter Conference Call on October 22, 2008
09/22/08Quidel Influenza Test Selected for FluSTAR(R) Surveillance Program
09/16/08Quidel to Present at the UBS 2008 Global Life Sciences Conference
07/23/08CORRECTING and REPLACING Quidel Reports Second Quarter 2008 Results
07/23/08Quidel Reports Second Quarter 2008 Results
07/09/08Quidel to Hold 2008 Second Quarter Conference Call on July 23, 2008
05/20/08Quidel and Prodesse Announce Flu and RSV Molecular Partnership
04/23/08Quidel Reports First Quarter 2008 Results
04/09/08Quidel to Hold 2008 First Quarter Conference Call on April 23, 2008
03/04/08Quidel Corporation and Susie's Cause Partner in Colorectal Cancer Awareness Event
02/29/08FDA Grants CLIA Waiver for Quidel's QuickVue(R) RSV Test
02/21/08Quidel Reports Fourth Quarter and Full Year 2007 Results
02/11/08Quidel to Hold 2007 Fourth Quarter and Year-End Financial Results Conference Call on February 21, 2008
01/15/08Quidel and bioMerieux Announce a Global Strategic Alliance in Rapid Diagnostics
12/06/07Quidel Corporation and Roche to Collaborate in Pilot Program for Influenza Management in U.S. This Flu Season
11/06/07Dr. Kenneth F. Buechler Appointed to Quidel Corporation Board of Directors
10/24/07Quidel Reports Strong Third Quarter Results
10/17/07Quidel to Hold 2007 Third Quarter Financial Results Conference Call on October 24
10/16/07Adventist Health System, Largest Not-for-Profit Health System in the U.S., Selects Quidel as Flu Test Supplier
10/08/07Physicians More Appropriately Prescribe Treatment after Rapid Flu and RSV Testing of Pediatric Patients
10/08/07Use of Quidel QuickVue(R) Rapid Flu Test in Nursing Homes Allows for More Rapid Recognition of Outbreaks and Appropriate Therapies
09/26/07Exclusive Agreement Announced Between Quidel Corporation and Roche Pharma AG
09/19/07Quidel to Present at the UBS 2007 Global Life Sciences Conference
07/26/07Quidel Reports Strong Second Quarter Results
07/17/07Quidel Corporation Announces Exclusive Licenses to Molecular Antiviral Resistance and Detection Technology for Influenza
07/16/07Quidel to Hold 2007 Second Quarter Financial Results Conference Call on July 26
06/26/07Quidel Announces Promotion of Scot M. McLeod to Senior Vice President, Operations
06/26/07Quidel Announces Appointment of Industry Veteran Richard C. Tarbox III as Senior Vice President, Corporate Development Officer
06/01/07Quidel Announces Mark E. Paiz Resignation
05/30/07Quidel to Present at the Bank of America 2007 Health Care Conference
04/26/07Quidel Reports Strong First Quarter Results with Revenues up 25%, Operating Income up 49%, Diluted EPS of $0.14
04/19/07Quidel to Hold 2007 First Quarter Financial Results Conference Call on April 26
03/27/07LabCorp Adopts Quidel Corporation's QuickVue(R) iFOB Test
03/12/07Quidel Authorizes Additional $25 Million under Stock Repurchase Program
02/22/07Quidel Corporation and Cholestech Corporation Partner to Offer ''Derm Kit'' to Help Dermatologists Achieve iPLEDGE(TM) Compliance
02/21/07Quidel Corporation and Scripps Hospital Partner in Colorectal Cancer Awareness Event
02/15/07Quidel Announces Strong Fourth Quarter and Full Year Results for 2006
02/07/07Quidel to Hold 2006 Fourth Quarter and Year-End Financial Results Conference Call on February 15
01/03/07Quidel Names John M. Radak Chief Financial Officer
12/19/06Quidel Announces Worldwide, Exclusive License for Novel DNA Microarray (MChip) for Global Influenza Surveillance
11/29/06Quidel to Present at BIO Drug/Device Summit 2006 on December 4
11/08/06Quidel to Present at BIOCOM San Diego Investor Conference on November 15
11/01/06Quidel Announces Third Quarter Results
10/18/06Quidel to Hold 2006 Third Quarter Financial Results Conference Call on November 1
09/20/06Quidel to Present at UBS Global Life Sciences on September 27
09/18/06Quidel Announces FDA 510(k) Clearance of Their New Rapid Test for Detection of Respiratory Syncytial Virus (RSV); RSV Causes Approximately 100,000 Hospitalizations in the U.S. Each Year(1)
09/07/06Quidel Announces CFO Retirement Effective March 31, 2007
08/02/06Quidel Announces Second Quarter Results; Worldwide Product Sales up 21%
07/19/06Quidel to Hold 2006 Second Quarter Financial Results Conference Call on August 2
06/06/06Quidel to Present at Pacific Growth Equities 2006 Life Sciences Growth Conference on June 13
04/26/06Quidel Announces Record First Quarter Results with Worldwide Product Sales up 24%, Diluted EPS of $0.15
04/19/06Quidel to Hold 2006 First Quarter Financial Results Conference Call on April 26
03/16/06Quidel Corporation Announces Strategic Business Partnership with Church & Dwight Co., Inc.
02/21/06Quidel Expands Influenza Testing in European Community; German School System and French Soccer Team Adopt the QuickVue(R) Influenza A+B Test
02/15/06Quidel Announces Strong Fourth Quarter Results; Reports Earnings from Continuing Operations of $0.28 Per Share
02/07/06Quidel Corporation Appoints Jack W. Schuler and Rod F. Dammeyer to Its Board of Directors
02/01/06Quidel to Hold 2005 Fourth Quarter and Year-End Financial Results Conference Call on February 15
01/20/06Quidel Corporation Appoints Renowned Leaders in the Diagnosis and Treatment of Infectious Disease to Medical Advisory Board
01/06/06Quidel Corporation Elaborates upon Flu Test Claims, Including Data for All Specimen Types
12/29/05Quidel's Flu Test Receives FDA Clearance for New Claims; Company Projects Strong Finish for 2005
10/26/05Quidel Announces Third Quarter Financial Results; Total Revenues up 47%; Worldwide Product Sales up 58%
10/12/05Quidel to Hold Third Quarter 2005 Financial Results Conference Call on October 26
09/26/05Quidel Announces Strategic Business Partnerships at ASBMR Conference; Specialty Products Group Expands Global Capabilities in Osteoporosis Products
09/15/05Quidel Joins Fight for Early Detection of Colon Cancer; Expands Product Portfolio to Target 50 Million U.S. Test Market for Fecal Occult Blood Tests
08/12/05Study Validates Sensitivity of Quidel Rapid Test to Detect Bacterial Vaginosis; Condition Accounts for over 10 Million Physician Office Visits in the U.S. Annually
08/01/05Quidel Corporation Appoints Renowned Experts in Reproductive Health to Advisory Board; Erudite Panel Rounds out Company's Clinical Expertise
07/27/05Quidel Reports Second Quarter Financial Results
07/14/05Quidel to Hold Second Quarter 2005 Financial Results Conference Call on July 27
06/14/05Quidel Announces Stock Repurchase Program
05/26/05Quidel to Present at Pacific Growth Equities Life Sciences Growth Conference on June 7
05/10/05Study Validates Higher Sensitivity of Quidel's QuickVue Influenza A+B Test among Rapid Flu Tests; University of Rochester Presents Research at Clinical Virology Symposium
05/10/05Quidel Reports First Quarter Financial Results; Conference Call to Begin at 2:00 p.m. PT/5:00 p.m. ET Today
05/04/05Quidel to Hold First Quarter 2005 Financial Results Conference Call on May 10
04/27/05Inverness Medical Innovations and Quidel Announce Settlement of Intellectual Property Litigation
04/27/05Quidel Reports Settlement of Inverness Litigation and 17% Increase in Total Revenues for First Quarter
04/12/05Quidel to Hold First Quarter 2005 Financial Results Conference Call on April 27
02/16/05Quidel Reports Strong Fourth Quarter Results
02/02/05Quidel Fourth Quarter and 2004 Financial Results Conference Call Alert
12/13/04Quidel Names Thomas D. Brown to Board of Directors; Addition of Veteran Abbott Laboratories Executive Expands Board to Seven
12/06/04Quidel Corporation Receives 2004 ``Best in Class'' Award from HPIS; Award Recognizes Highest Year-to-Date Growth in the Immunology Reagents/Supplies Category
11/22/04Quidel Affirms Confidence in Patent Litigation
11/01/04Quidel Names Thomas J. Foley Chief Technology Officer
10/27/04Quidel Reports Third Quarter Financial Results
10/21/04Quidel Launches flutest.com; Interactive Web Site Delivers Practical Flu Solutions For Consumers
10/14/04Quidel Third Quarter 2004 Results Conference Call Alert
08/23/04Quidel Names Caren L. Mason Chief Executive Officer; Former GE General Manager Women's Healthcare Brings To Quidel Strong Customer and Operating Skills
07/28/04Quidel Reports Second Quarter Financial Results
07/14/04Quidel Second Quarter 2004 Results Conference Call Alert
07/13/04Quidel Corporation Announces Departure of S. Wayne Kay, President and CEO; Mark E. Paiz Promoted to Chief Operating Officer
07/09/04Quidel Expects Second Quarter Total Revenues of $14.3 Million and Estimates Net Loss of $0.12 Per Share; Quidel Suspends 2004 Financial Guidance
06/07/04Quidel to Present at Pacific Growth Equities Life Sciences Growth Conference on June 10 at 1:30 p.m. Pacific Time
06/02/04Quidel Board Elects Mark A. Pulido Chairman
04/28/04Quidel Reports First Quarter Financial Results
04/14/04Quidel First Quarter 2004 Results Conference Call Alert
04/07/04Quidel Expects First Quarter Total Revenues of $19.7 Million and Estimates EPS of $0.01; Results Reflect Softness in U.S. and Japan Markets for Influenza and Strep A Tests
03/08/04Quidel to Present at the S.G. Cowen 24th Annual Health Care Conference on March 10, 2004 at 11:15 a.m. EST
02/27/04Quidel Revises 2004 EPS Guidance Due to Expected Litigation Expenses for Previously Announced Patent Lawsuits
02/25/04FDA Grants CLIA-Waived Status to Quidel's QuickVue Influenza A+B Test
02/23/04Quidel Files Patent Infringement Lawsuit against Inverness Medical Innovations and Advises of Other New Litigation
02/11/04Quidel Reports Record Fourth Quarter Financial Results; Company Raises 2004 Financial Guidance; Chairman Andre de Bruin Announces Retirement
01/28/04Quidel Fourth Quarter and Full-Year 2003 Results Conference Call Alert
10/29/03Quidel Reports Third Quarter Revenue and Margin Gains; Restructuring Largely Completed, Early Indications of Strong Influenza Season
10/15/03Quidel Third Quarter 2003 Conference Call Alert
09/17/03Quidel Signs Distributor Agreements in Germany and Italy
09/15/03Quidel Bolsters Management Team with the Addition of Global Sales and Marketing Senior Vice President
09/08/03Quidel Expands Distribution of QuickVue Strep A Test to Physician Sales and Service
07/30/03Quidel Reports Second Quarter Revenue and Margin Gains; Company Confirms 2003 and 2004 Guidance
07/10/03Quidel Second Quarter 2003 Conference Call Alert
06/03/03Quidel Executives Invited by HHS Secretary Thompson and FDA Commissioner McClellan to Participate in Meeting on Developing Diagnostic Tests for SARS
04/29/03Quidel Reports Strong First Quarter Revenues; Revises 2003 Guidance Upward and Introduces 2004 Guidance; Restructuring Initiative Undertaken to Drive Shareholder Value
04/11/03Quidel First Quarter 2003 Conference Call Alert
04/02/03Quidel QuickVue Influenza Test Offers 10-Minute Test Results to Evaluate Respiratory Symptoms
03/27/03Quidel Streamlines Structure of Executive Team
03/17/03Quidel to Present at the S.G. Cowen 23rd Annual Health Care Conference on March 19, 2003 at 10:00 A.M. EST
02/10/03Quidel Reports Fourth Quarter Pre-Tax EPS of $0.07, Revenues of $22.8 Million
01/29/03Quidel to Present at The Wall Street Analyst Forum on February 12, 2003 at 9:00 a.m. EST
01/27/03Quidel Fourth Quarter Conference Call Alert
12/17/02Quidel Introduces 2003 Financial Guidance
12/06/02Quidel Corporation to Present at CCBN Virtual Healthcare Conference
12/03/02Quidel 2003 Financial Guidance Conference Call Alert
11/20/02Quidel Announces Urinalysis Automated Analyzer Now Available Worldwide
11/20/02Quidel Announces Worldwide Commercialization of its Layered Thin Film™ Products
10/30/02Quidel Reports Third Quarter Financial Results
10/09/02Quidel Appoints Donald J. Lovre as Corporate Accounts Manager
10/08/02Quidel Third Quarter Conference Call Alert
10/03/02Quidel Updates Third Quarter Financial Guidance
09/27/02Corporate Profile for Quidel Corporation, dated Sept. 27, 2002
09/17/02Quidel Corporation's QuickVue(R) Dipstick Strep A Test Receives Governmental Approval in Japan
08/29/02Quidel to Present at Wells Fargo Securities' Class of 2002 Conference
08/29/02Quidel Receives Additional Patent Protection On Layered Thin Film Technology
08/28/02Quidel Names Mark A. Pulido to Its Board of Directors; Adds Impressive Healthcare Channel Management and Fortune 50 Expertise
07/31/02Quidel Meets Consensus Pre-Tax EPS on Record Second Quarter Revenues
07/30/02Quidel Introduces New Urinalysis Diagnostic Product, The UrinQuick(TM) Urine Chemistry Analyzer
07/29/02Quidel Launches Tests for Infectious Vaginitis, QuickVue(R) Advance pH and Amines and QuickVue(R) Advance G. Vaginalis Tests
07/11/02Quidel Joins Russell 3000(R) Index
07/10/02Quidel Second Quarter Conference Call Alert
05/13/02Quidel Corporation Amends Shareholder Rights Agreement to Permit Kopp Investment Advisors to Increase Ownership Position to 20%
05/09/02Quidel Announces Appointment of New Position for Vice President, Regulatory/Clinical and Quality Systems
05/07/02Quidel Corporation Recognized As 2002 Allegiance Healthcare 'SP Partner of the Year'
04/30/02Quidel Reports First Quarter Pre-Tax EPS of $0.09 on Total Revenues of $21.2M
04/11/02Quidel *First Quarter Conference Call Alert*
04/11/02Quidel Appoints Ernst & Young as Independent Public Accountants
03/07/02Quidel to Present at SG Cowen 22nd Annual Health Care Conference, March 12, 2002
02/12/02Quidel Reports Record Fourth Quarter Pre-Tax EPS of $0.11
01/23/02Quidel *Fourth Quarter Conference Call Alert
01/23/02Quidel *Fourth Quarter Conference Call Alert*
01/14/02Quidel's QuickVue(R) Influenza Test Receives Specific Reimbursement Code Just in Time for Flu Season
12/19/01Nation's Largest Osteoporosis Study Finds High Incidence of Undetected Cases
11/27/01Quidel's Metra(TM) DPD Osteoporosis Test Gains Mandatory National Medicare Coverage
11/19/01Quidel Corporation -Nasdaq: QDEL- Posts Information On the Web to Educate the Public About Influenza Testing and Pathogens That Can Cause Flu-like Symptoms
11/01/01Quidel Reports Record Third Quarter Net Sales
10/25/01Quidel *Third Quarter Conference Call Alert
10/25/01Quidel *Third Quarter Conference Call Alert*
10/17/01Quidel Corporation Offers Free Flu Tests to Public Health Agencies in Bioterrorism Planning
10/10/01Quidel's QuickVue(R) Influenza Test Launched in Japan
10/02/01Quidel To Present at UBS Warburg Global Life Sciences Conference, October 12, 2001
08/27/01Quidel to Present at Wells Fargo Van Kasper Growth Stock Conference, Sept 5, 2001
08/20/01Quidel Names Paul Landers as Chief Financial Officer
08/14/01Quidel Promotes S. Wayne Kay to CEO; Andre de Bruin Elected Chairman of the Board
08/02/01Quidel Receives Additional Patent Protection on LTF Technology; Patent Covers Use of Company Technology to Detect Vaginal Clue Cells
07/31/01Quidel Reports Second Quarter Results
07/31/01Quidel QuickVue(R) Dipstick Strep A Test Receives CLIA-Waived Status
07/24/01Quidel Corporation Wins Prestigious Supplier of the Year Award; Award Recognizes Best Sales Growth in the Primary Care Market
07/24/01Quidel *Conference Call Alert*
07/10/01Quidel Receives Significant Patent Protection on LTF Technology
05/30/01Quidel Corporation Announces Officer Resignation
05/17/01Quidel Corporation Receives FDA Clearance for New Strep A Test
04/26/01Quidel Corporation Announces First Quarter Results
04/26/01QUIDEL Corporation Confirms Its Achievement of Earnings Expectations
04/19/01Quidel Corporation Announces Conference Call Invitation
03/21/01Quidel Corporation Announces Issuance of Two U.S. Patents
02/23/01Quidel Announces European Patent Decision - German Court Upholds Company's Patent for Immunodiagnostic Device
02/15/01Quidel Reports Financial Results for the Quarter and Year Ended December 2000
02/08/01Quidel Corporation (Nasdaq: QDEL) Conference Call Alert
02/01/01Quidel Launches New Biochemical Bone Marker Test
01/03/01Quidel Receives ISO Certification
12/19/00Quidel Announces Over-The-Counter Flu Test in European Countries
12/13/00Quidel Corporation Appoints S. Wayne Kay President, COO
11/09/00Quidel Introduces New and Improved Test for Peptic Ulcers
10/31/00Quidel Corporation to Acquire Litmus Concepts
10/31/00Quidel Corporation (Nasdaq: QDEL) Conference Call Alert
10/26/00Quidel Reports Third Quarter Earnings
10/12/00Quidel Rapid Flu Test Now Available for Widespread Use in the U.S.
09/18/00Quidel Comments on Earnings
08/16/00Quidel Announces U.S. Market Launch of Urinalysis Product
08/08/00Quidel Receives FDA Approval to Market Osteoporosis Device
08/01/00Quidel's Second Quarter Sales Increase 60%
06/27/00Quidel Comments on New Product Launches and Second Quarter Earnings
06/09/00Lin Haelewyn Promoted to Senior Vice President, And Appointed an Officer of Quidel Corporation
05/04/00Quidel Receives Approval to Market Influenza Test in Canada
04/25/00Quidel's First Quarter Sales Increase 66%, Pretax Profits More Than Double to $1.9 Million
02/17/00Quidel Reports Financial Results for the Three and Nine Months Ended December 31, 1999 - New Fiscal Year End
02/04/00Quidel Files to Register Common Stock Underlying Publicly Traded Warrants
02/01/00Quidel Comments on Earnings Outlook and Milestone Payment From Sumitomo
01/19/00Got The Flu? Are You Sure?
12/22/99Quidel Corporation Announces Sale/Leaseback of its San Diego Headquarters
12/14/99Quidel Corporation is Exclusive Licensee for Patent Granted for Peptide to be Used in Managing Osteoporosis
12/08/99Quidel Corporation Completes Acquisition of Urine Test Strip Business; Acquisition Expands Point-of-Care Diagnostic Products
12/07/99Quidel Begins Shipping Influenza Point-of-Care Diagnostic Test; 10-Minute QuickVue Influenza Test Available This Flu Season
11/03/99Quidel Reports Second Quarter Fiscal Year 2000 Financial Results
09/27/99Quidel Receives FDA Clearance for Influenza Point-of-Care Diagnostic Test
09/02/99Quidel Receives CLIA-Waived Status for H. pylori Diagnostic Test
08/18/99QUIDEL Receives FDA Clearance for Improved H. Pylori Diagnostic Test; Good News for Ulcer Sufferers
08/16/99Quidel Corporation Names New Board Member
07/22/99Quidel Reports First Quarter Fiscal Year 2000 Financial Results
06/07/99QUIDEL Corporation Signs Agreement to Acquire Metra Biosystems, Inc. in All Cash Transaction
05/17/99Quidel Reports Fourth Quarter and Fiscal 1999 Financial Results
05/13/99Quidel Seeks FDA Clearance For Point-Of-Care Influenza Diagnostic
05/12/99QUIDEL Joins Merck-Medco in Peptic Ulcer Disease Pilot Program
04/11/99Quidel Corporation Completes Acquisition of Metra Biosystems; Quidel Expands Product Line Into Osteoporosis Diagnostics